Showing 341 - 360 results of 25,426 for search '(( significant ((linear decrease) OR (clinical case)) ) OR ( significant decrease decrease ))', query time: 0.66s Refine Results
  1. 341

    Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations. by Denis Mustafov (19137870)

    Published 2025
    “…<b>(D)</b> Similarly, U251MG cells showed significantly decreased clonogenic potential upon 100ΜM SHG-44 treatment when compared to 100ΜM cis-platin and the untreated control. …”
  2. 342
  3. 343
  4. 344

    The figure shows that <i>R</i><sub>0</sub> decreases significantly under control strategies, particularly at temperatures near the peak transmission range, indicating the effectiveness of control mechanisms applied. by Lukas Degu Petros (22097332)

    Published 2025
    “…<p>The figure shows that <i>R</i><sub>0</sub> decreases significantly under control strategies, particularly at temperatures near the peak transmission range, indicating the effectiveness of control mechanisms applied.…”
  5. 345
  6. 346
  7. 347
  8. 348
  9. 349
  10. 350
  11. 351
  12. 352
  13. 353

    Table 1_Dual variants of uncertain significance in a case of hyper-IgM syndrome: implications for diagnosis and management.docx by Nourhen Agrebi (14151222)

    Published 2025
    “…Background<p>Hyper-IgM syndrome (HIGM) is a genetic immunodeficiency characterized by elevated to normal IgM levels and decreased IgG, IgA, and IgE. The overlapping clinical presentations of different gene mutations complicate diagnosis and management.…”
  14. 354

    Image 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

    Published 2025
    “…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  15. 355

    Image 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

    Published 2025
    “…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  16. 356
  17. 357
  18. 358
  19. 359
  20. 360